Louisville, Ky.-based ScionHealth will begin purchasing certain bulk drugs from Mark Cuban's Cost Plus Drug Co., the 94-hospital system said May 1. This marks Cost Plus Drugs' second health system partnership. 

The Federal Trade Commission sent letters to 10 drugmakers April 30 warning them that hundreds of patent listings for 20 drugs are invalid. The agency said "junk" listings keep drug prices high by stalling generic competition. 

Amazon's first-quarter earnings increased 225% in 2024 compared to last year, and the company listed its pharmacy services as one of its recent wins. 

Franklin, Tenn.-based Community Health Systems was the first health system to partner with and buy medicines manufactured by Mark Cuban Cost Plus Drug Co., and expects the partnership to result in significant advantages for its hospitals.

 The FDA has granted full approval for Pfizer's Tivdak (tisotumab vedotin-tftv) to treat cervical cancer in patients whose disease has progressed on or after chemotherapy. 

California's drug label, CalRx, is teaming up with Amneal Pharmaceuticals to offer naloxone at a 40% discount, Gov. Gavin Newsom said April 29.

Pfizer's first FDA-approved gene therapy is one of the most expensive medications in the U.S.

As some formularies begin to favor biosimilars, CVS Health and Cigna Group's Evernorth are veering further into the biosimilar business, The Wall Street Journal reported April 29. 

The term "hospital pharmacy" is becoming a misnomer.

In the first three months of 2024, the U.S. reached a record with 323 ongoing medication shortages — the highest number since 2001. 

West Reading, Pa.-based Tower Health recently promoted Stephanie Goldman, PharmD, from a hospital pharmacy leadership role to a systemwide job. 

Walgreens is expanding its specialty pharmacy offerings, including gene and cell therapy services, the company said April 25. 

Keytruda (pembrolizumab) was nonfederal hospitals' costliest drug expense in 2023, according to research published April 24 in the American Journal of Health-System Pharmacy. 

More than $38 billion was spent in the U.S. on Ozempic and Wegovy (semaglutide) in 2023 — a 100% uptick from 2022 expenditure data, according to research published April 24 in the American Journal of Health-System Pharmacy. 

The American Society of Health-System Pharmacists has named eight candidates for its board of directors.

Eli Lilly will acquire a Wisconsin-based injectable manufacturing facility from Nexus Pharmaceuticals, a drugmaker in Illinois. 

For about five years, federal auditors have enforced confusing requirements for residency programs, according to the American Society of Health-System Pharmacists, which released a toolkit April 18 to safeguard these programs. 

Emory Healthcare recently promoted Ryan Haumschild, PharmD, to the role of vice president of ambulatory pharmacy. 

After investigating the safety of CAR-T cell drugs, the FDA decided to include a serious risk on the boxed warnings of six approved immunotherapies. 

Community Health Systems' hospitals in Texas and Pennsylvania now stock epinephrine manufactured by Mark Cuban Cost Plus Drug Co.